Influence of immunosuppressive drugs on cell-induced graft tolerance

Current Opinion in Organ Transplantation

Volumn 9, Issue 3, 2004, Pages 307-313

  Heitger, Andreas ^a   Blaha, Peter ^b   Bigenzahn, Sinda ^b   Muehlbacher, Ferdinand ^b   Wekerle, Thomas ^b  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bone marrow transplantation; Immunosuppressive drugs; Mixed chimerism; Tolerance

Indexed keywords

EID: 33444473953     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/01.mot.0000134873.10331.5c     Document Type: Review

References (47)

1. Dey B, Sykes M, Spitzer TR: Outcomes of recipients of both bone marrow and solid organ transplants. A review. Medicine (Baltimore) 1998, 77:355-369.
2. Wekerle T, Sykes M: Mixed chimerism and transplantation tolerance. Annu Rev Med 2001, 52:353-370.
3. Wekerle T, Blaha P, Koporc Z, et al.: Mechanisms of tolerance induction through the transplantation of donor hematopoietic stem cells: central versus peripheral. Transplantation 2003, 75:21S-25S.
4. Lutz MB, Schuler G: Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trend Immunol 2002, 23:445-449.
5. Reddy P, Ferrara JL: Immunobiology of acute graft-versus-host disease. Blood Rev 2003, 17:187-194.
6. Slavin S, Morecki S, Weiss L, et al.: Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy-from bench to patient bedside. Semin Oncol 2004, 31:4-21.
7. Bacigalupo A: Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT). Bone Marrow Transplant 2002, 29:191-195.
8. Bacigalupo A: Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus. Bone Marrow Transplant 2004, 33:691-696.
9. Vogelsang GB, Lee L, Bensen-Kennedy DM: Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med 2003, 54:29-52.
10. Jacobsohn DA: Emerging therapies for graft-versus-host disease. Expert Opin Emerg Drugs 2003, 8:323-338.
11. Storb R, Yu C, Wagner JL, et al.: Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997, 89:3048-3054.
12. Vogelsang GB: How I treat chronic graft-versus-host disease. Blood 2001, 97:1196-1201.
13. Nikolic B, Zhao G, Swenson K, Sykes M: A novel application of cyclosporine A in nonmyeloablative pretransplant host conditioning for allogeneic BMT. Blood 2000, 96:1166-1172.
14. Hale D, Gottschalk R, Umemura A, et al.: Establishment of stable multilineage hematopoietic chimerism and donor-specific tolerance without irradiation. Transplantation 2000, 69:1242-1251.
15. Hale D, Gottschalk R, Umemura A, et al.: Immunologic mechanisms in tolerance produced in mice with nonradiation-based lymphoablation and donorspecific bone marrow. Transplantation 2002, 74:477-484.
16. Matloubian M, Lo C, Cinamon G, et al.: Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004, 427:355-360.
17. Kim Y-M, Sachs T, Asavaroengchai W, et al.: Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clin Invest 2003, 111:659-669.
18. Lee R, Kuhr C, Sale G, et al.: FTY720 does not abrogate acute graft-versushost disease in the dog leukocyte antigen-nonidentical unrelated canine model. Transplantation 2003, 76:1155-1158.
19. Xun CQ, Little MT, Zellmer E, et al.: What role for FTY720, a novel immunosuppressive agent, in canine nonmyeloablative hematopoietic stem cell transplantation? Transplantation 2002, 73:310-313.
20. Storb R, Yu C, Zaucha JM, et al.: Stable mixed chimerism in dogs given donor antigen, CTLA4lg, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. Blood 1999, 94:2523-2529.
21. Hogan W, Little M-T, Zellmer E, et al.: Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates. Biol Blood Marrow Transplant 2003, 9:489-495.
22. Zaucha J, Yu C, Zellmer E, et al.: Effects of extending the duration of postgrafting immunosuppression and substituting granulocyte-colony-stimulating factor-mobilized peripheral blood mononuclear cells for marrow in allogeneic engraftment in a nonmyeloablative canine transplantation model. Biol Blood Marrow Transplant 2001, 7:513-516.
23. Kuhr C, Allen M, Junghanss C, et al.: Tolerance to vascularized kidney grafts in canine mixed hematopoietic chimeras. Transplantation 2002, 73:1487-1493.
24. Spitzer TR, Delmonico F, Tolkoff-Rubin N, et al.: Combined histocompatible leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999, 68:480-484.
25. Bühler LH, Spitzer TR, Sykes M, et al.: Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 2002, 74:1405-1409.
26. Sykes M, Preffer F, Mcaffee S, et al.: Mixed lymphohematopoietic chimerism and graft-vs-lymphoma effects are achievable in adult humans following nonmyeloablative therapy and HLA-mismatched donor bone marrow transplantation. Lancet 1999, 353:1755-1759.
27. Kawai T, Cosimi AB, Colvin RB, et al.: Mixed allogeneic chimerism and renal allograft tolerance in cynomologous monkeys. Transplantation 1995, 59:256-262.
28. Sykes M: Mixed chimerism and transplant tolerance. Immunity 2001, 14:417-424.
29. Kurtz J, Ito H, Wekerle T, et al.: Mechanisms involved in the establishment of tolerance through costimulatory blockade and BMT: Lack of requirement for CD40L-mediated signaling for tolerance or deletion of donor-reactive CD4+ cells. Am J Transplant 2001, 1:339-349.
30. Adams AB, Durham MM, Kean L, et al.: Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression. J Immunol 2001, 167:1103-1111.
31. Taylor PA, Lees CJ, Waldmann H, et al.: Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions. Blood 2001, 98:467-474.
32. Taylor PA, Lees CJ, Wilson JM, et al.: Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions. Blood 2002, 100:3400-3407.
33. Kurtz J, Lie A, Griffith M, et al.: Lack of role for CsA-sensitive or Fas pathways in the tolerization of CD4 T cells via BMT and anti-CD40L. Am J Transplant 2003, 3:804-816.
34. Blaha P, Bigenzahn S, Koporc Z, et al.: The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood 2003, 101:2886-2893.
35. Adams AB, Shirasugi N, Jones TR, et al.: Conventional immunosuppression is compatible with costimulation blockade-based, mixed chimerism tolerance induction. Am J Transplant 2003, 3:895-901.
36. Wu T, Sozen H, Luo B, et al.: Rapamycin and T cell costimulatory blockade as post-transplant treatment promote fully MHC-mismatched allogeneic bone marrow engraftment under irradiation-free conditioning therapy. Bone Marrow Transpl 2002, 29:949-956.
37. Wekerle T, Kurtz J, Bigenzahn S, et al.: Mechanisms of transplant tolerance induction using costimulatory blockade. Curr Opin Immunol 2002, 14:592-600.
38. Trambley J, Bingaman AW, Lin A, et al.: Asialo GM1(+) CD8 (+) T cells play a critical role in costimulation blockade-resistant allograft rejection. J Clin Invest 1999, 104:1715-1722.
39. Ito H, Kurtz J, Shaffer J, Sykes M: CD4 T cell-mediated alloresistance to fully MHC-mismatched allogeneic bone marrow engraftment is dependent on CD40-CD40 ligand interactions, and lasting T cell tolerance is induced by bone marrow transplantation with initial blockade of this pathway. J Immunol 2001, 166:2970-2981.
40. Jones ND, Van Maurik A, Hara M, et al.: CD40-CD40 ligand-independent activation of CD8+ T cells can trigger allograft rejection. J Immunol 2000, 165:1111-1118.
41. Iwakoshi NN, Mordes JP, Markees TG, et al.: Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner. J Immunol 2000, 164:512-521.
42. Li Y, Li XC, Zheng XX, et al.: Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999, 5:1298-1302.
43. Nashan B, Moore R, Amlot P, et al.: The CHIB 201 International Study Group: Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997, 350:1193-1198.
44. Vincenti F, Kirkman R, Light S, et al.: Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998, 338:161-165.
45. Kreis H, Cisterne JM, Land W, et al.: Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000, 69:1252-1260.
46. Wekerle T, Kurtz J, Ito H, et al.: Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000, 6:464-469.
47. Durham MM, Bingaman AW, Adams AB, et al.: Administration of anti-CD40 ligand and donor bone marrow leads to hematopoietic chimerism and donorspecific tolerance without cytoreductive conditioning. J Immunol 2000, 165:1-4.